Xbrane Biopharma has set a goal of capturing a quarter of Lucentis (ranibizumab) volumes in Europe and the US with its Xlucane biosimilar, which the Swedish company forecasts will generate annual sales of €350m ($390m) three years after launch. Currently, the firm is expecting its first Xlucane sales in the first quarter of 2022.
“The sales target is based on reaching a volume market share of 25% in Europe and US of the current...






